Department Title Author Short Description Video Url
DRUG DESIGN Public Lecture—Mutant Ribosomes and the Action of Antibiotics SLAC National Accelerator Laboratory The ribosome, found in all living cells, is the molecular machine that builds proteins. View
DRUG DESIGN Drug Discovery: What’s the difference between structure based and ligand based virtual screening? CCDCCambridge Watch Abhik Mukhopadyay, Research and Applications Scientist at CCDC, to learn the difference between structure based and ligand based. View
DRUG DESIGN Structure Based Drug Discovery: Case study and Conclusion IIT Roorkee July 2018 This lecture covers a beautiful case study of designing a novel inhibitor against drug-resistant Mycobacterium tuberculosis beta-lactamase BlaC. View
DRUG DESIGN Structure based & Ligand based drug design : Basics & Advances JSS Academy of Higher Education & Research View
DRUG DESIGN Fredrik Rahm (Sprint Bioscience): Improving Workflows for Structure-Based Drug Design ChemAxon At Sprint Bioscience we use fragment-based techniques to quickly find high-quality chemical starting points for our small molecule drug discovery projects. View
DRUG DESIGN Schrödinger SBGrid Consortium Schrödinger Introduction to Structure-Based Drug Design View
DRUG DESIGN Pharmacophore-based virtual screening of pyridopyridazin-6-ones – Video abstract 50738 Dove Medical Press Video abstract of original research paper “Pharmacophore generation, atom-based 3D-QSAR, docking, and virtual screening studies of p38-α mitogen activated protein kinase inhibitors: pyridopyridazin-6-ones (part 2) View
DRUG DESIGN Jenny Viklund & Fredrik Rahm (Sprint Bioscience): Marvin Live for structure-based drug design ChemAxon How to make better molecules faster is a key challenge in preclinical drug discovery. View
DRUG DESIGN Structure Based Drug Design An Overview Dr. Anwar R. Shaikh Structure Based Drug Design An Overview View
DRUG DESIGN webinar recording: structure-based drug design of selective Drp1 inhibitors BioSolveITTutorials The mitochondrial protein dynamin-related protein (Drp1) has been implicated in the development of a number of diseases, including cancer, heart disease and dementia. To date, no direct small molecule inhibitors of human Drp1 have been identified. View